945TiP JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)
Machiels J, Burtness B, Harrington K, Saba N, Tahara M, Crossman T, Hua L, Perera A, Theti D, Zografos E, Siu L. 945TiP JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC). Annals Of Oncology 2024, 35: s655. DOI: 10.1016/j.annonc.2024.08.2145.Peer-Reviewed Original ResearchLocally advanced unresectable headLA-HNSCCSequential therapyChemoradiationPlaceboDostarlimabTherapyPatients